Perspectives: Towards a peptide-based vaccine against hepatitis C virus

Molecular Immunology

Volumn 38, Issue 6, 2001, Pages 475-484

  Hunziker, Isabelle P ^a   Zurbriggen, Rinaldo ^b   Glueck, Reinhard ^b   Engler, Olivier B ^a   Reichen, Jürg ^c   Dai, Wen Juan ^a   Pichler, Werner J ^a   Cerny, Andreas ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b Berna Biotech Ltd   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Ospedale Civico Lugano   (Switzerland)

Author keywords

Hepatitis C virus; Peptides; Vaccine development; Virosomes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HEMAGGLUTININ; HEPATITIS A VACCINE; HEPATITIS C VACCINE; HLA A2 ANTIGEN; INFLEXAL; INFLUENZA VACCINE; LIVE VACCINE; PHOSPHOLIPID; SIALIDASE; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPOTENTIATION; INFECTION PREVENTION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS REPLICATION;

HEPACIVIRUS; HEPATITIS C; HLA-A2 ANTIGEN; HUMANS; ORTHOMYXOVIRIDAE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; VACCINES, VIROSOME; VIRAL HEPATITIS VACCINES;

HEPATITIS A VIRUS; HEPATITIS C VIRUS; INFLUENZA VIRUS;

EID: 0035657650     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(01)00083-9     Document Type: Review

References (85)

1. T cell priming versus T cell tolerance induced by synthetic peptides
2. Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology
3. Formation of virosomes from influenza subunits and liposomes
4. Epidemiology of hepatitis C
5. Correlation between virus genotype and chronicity rate in acute hepatitis C
6. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes
7. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
8. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
9. Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes
10. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes comparison of the costimulating support provided by helper T cells and lipoamino acid
11. Prevalence of the genotypes of the hepatitis C virus in Spanish drug addicts with chronic hepatitis C
12. Hepatitis C virus: Molecular biology and genetic variability
13. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes)
14. Genetic heterogeneity of hepatitis C virus: Quasi-species genotypes
15. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
16. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
17. The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses
18. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
19. Persistence of HCV despite antibodies to both putative envelope glycoproteins
20. Cytotoxic T cells and viral hepatitis
21. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
22. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis
23. Virosomes reconstituted from human immunodeficiency virus proteins and lipids
24. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans
25. Comparison of serum and liver hepatitis C virus quasi-species in HCV-related hepatocellular carcinoma
26. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy
27. RNA virus quasi-species: Significance for viral disease and epidemiology
28. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees
29. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
30. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
31. Simultaneous vaccination for hepatitis A and B
32. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A
33. Immunogenicity of new virosome influenza vaccine in elderly people
34. Clinical implications of viral quasi-species heterogeneity in chronic hepatitis C
35. Engineered liposomes and virosomes for delivery of macromolecules
36. Cross-presentation, dendritic cells, tolerance and immunity
37. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: A randomized controlled trial
38. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes (IRIV) as a non-live prototype vaccine against hepatitis C virus
39. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
40. Adjuvant activity of incomplete Freund's adjuvant
41. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition
42. Virosomes: Evolution of the liposome as a targeted drug delivery system
43. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide
44. Hepatitis vaccines
45. Evaluation of hepatitis C virus protein epitopes for vaccine development
46. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A
47. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses
48. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1
49. Effect of adjuvant formulations on the induction of virus-neutralizing and virus-binding antibodies by chemosynthetic peptides of VP1 of foot-and-mouth-disease virus
50. Processing pathways of the hepatitis C virus proteins
51. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
52. Inactivated virosome hepatitis A vaccine
53. In vivo loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity
54. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasi-species nature of HCV genome distribution
55. Infectious entry pathway of influenza virus in a canine kidney cell line
56. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres
57. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres
58. Virosomes as carriers for combined vaccines
59. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins
60. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines
61. Expression of hepatitis C virus proteines does not interfere with major histocompatibility complex class I processing and presentation in vitro
62. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens
63. Development of a plant-derived subunit vaccine candidate against hepatitis C virus
64. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
65. Differences in hypervariable region 1 quasi-species of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver
66. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
67. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee
68. Structural and immunogenic characteristics of rabies immunosomes
69. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
70. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo
71. Characterization of hepatitis C virus core-specific immune responses primed in Rhesus macaques by a nonclassical ISCOM vaccine
72. Structure, genomic organization, replication and variability of hepatitis C virus
73. Challenges for development of hepatitis C virus vaccines
74. The hepatitis C virus: Overview
75. Peptide-induced antiviral protection by cytotoxic T cells
76. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
77. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines
78. Variability of hepatitis C virus
79. A proposed system for the nomenclature of hepatitis C viral genotypes
80. Quasi-species nature of hepatitis C virus (HCV) in patients with chronic hepatitis C with mixed HCV subtypes
81. Induction of virus-specific cytotoxic T lymphocytes by in vivo electric administration of peptides
82. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
83. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus
84. Immunology taught by viruses
85. Prospects for hepatitis C vaccine